Cipher Capital LP Has Lifted By $563,040 Its Garmin LTD (GRMN) Holding; Insys Therapeutics Has 1.33 Sentiment

November 18, 2018 – By Robert Judd

Garmin Ltd. (NASDAQ:GRMN) Logo

Cipher Capital Lp increased Garmin Ltd (GRMN) stake by 166.47% reported in 2018Q2 SEC filing. Cipher Capital Lp acquired 9,384 shares as Garmin Ltd (GRMN)’s stock rose 9.98%. The Cipher Capital Lp holds 15,021 shares with $916,000 value, up from 5,637 last quarter. Garmin Ltd now has $12.36B valuation. The stock increased 0.40% or $0.26 during the last trading session, reaching $65.48. About 815,929 shares traded. Garmin Ltd. (NASDAQ:GRMN) has risen 31.61% since November 18, 2017 and is uptrending. It has outperformed by 15.99% the S&P500. Some Historical GRMN News: 11/04/2018 – The zūmo® 396 motorcycle navigator from Garmin® brings live features to stay connected on every ride; 13/03/2018 – NORDEA ROLLS OUT PAYMENT SOLUTION FOR FITBIT, GARMIN SMARTWATCH; 06/03/2018 – GARMIN INTERNATIONAL – FLIGHT PLANS MAY BE TRANSFERRED FROM FLTPLAN GO TO GARMIN PILOT APPLICATION FOR IOS AND ANDROID USERS; 02/05/2018 – GARMIN 1Q REV. $711M, EST. $669.0M; 15/05/2018 – Squarepoint Ops Adds Garmin, Exits IBM, Buys More Lululemon: 13F; 02/05/2018 – Garmin Sees FY18 Adj EPS $3.05; 18/04/2018 – Garmin® introduces the Edge® 130 – a compact GPS bike computer designed for use on any ride; 18/04/2018 – Garmin® hosts second Connect IQ™ Developer Summit, announces Connect IQ 3.0 with new apps from Trailforks, Yelp, iHeartRadio; 04/05/2018 – Garmin Conference Call Scheduled By Aliya Capital for May. 11; 03/05/2018 – Introducing inReach® Mini from Garmin®, a small but mighty two-way satellite communicator for any adventure

Insys Therapeutics Inc (INSY) investors sentiment increased to 1.33 in Q2 2018. It’s up 0.58, from 0.75 in 2018Q1. The ratio has increased, as 40 hedge funds increased or started new holdings, while 30 decreased and sold stock positions in Insys Therapeutics Inc. The hedge funds in our database now possess: 12.52 million shares, up from 12.41 million shares in 2018Q1. Also, the number of hedge funds holding Insys Therapeutics Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 13 Reduced: 17 Increased: 26 New Position: 14.

Orbimed Advisors Llc holds 0.3% of its portfolio in INSYS Therapeutics, Inc. for 3.51 million shares. Gam Holding Ag owns 83,940 shares or 0.02% of their US portfolio. Moreover, Tci Wealth Advisors Inc. has 0.02% invested in the company for 7,766 shares. The Texas-based Bridgeway Capital Management Inc has invested 0.01% in the stock. Panagora Asset Management Inc, a Massachusetts-based fund reported 185,009 shares.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $527.32 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

More notable recent INSYS Therapeutics, Inc. (NASDAQ:INSY) news were published by: which released: “INSYS Therapeutics to Assess Strategic Alternatives for Opioid-Related Assets” on November 05, 2018, also with their article: “INSYS up 6% premarket on encouraging data on opioid overdose nasal spray” published on November 01, 2018, published: “INSYS Therapeutics to Report Third Quarter 2018 Results on Nov. 5” on October 22, 2018. More interesting news about INSYS Therapeutics, Inc. (NASDAQ:INSY) were released by: and their article: “Consolidated Research: 2018 Summary Expectations for Insys Therapeutics, Achaogen, Astec Industries, Central …” published on October 29, 2018 as well as‘s news article titled: “75 Biggest Movers From Yesterday” with publication date: November 07, 2018.

The stock decreased 1.80% or $0.13 during the last trading session, reaching $7.1. About 249,013 shares traded. INSYS Therapeutics, Inc. (INSY) has declined 6.48% since November 18, 2017 and is downtrending. It has underperformed by 22.10% the S&P500. Some Historical INSY News: 14/05/2018 – U.S. and 5 States Add Their Support to Lawsuit Filed by The Employment Law Group against Insys Therapeutics; 16/03/2018 – HQGE Unveils Extensive Cannabidiol (CBD Oil) Database, Teams with Hemp, Inc. to Produce and Distribute High-Quality Customizabl; 19/04/2018 – GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT; 08/03/2018 – INSYS 4Q ADJ LOSS/SHR 61C, EST. LOSS/SHR 14C; 13/03/2018 – NULL GW PHARMACEUTICALS ANNOUNCES RECEIPT OF NOTICES OF ALLOWANCE BY THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) FOR FIVE NEW EPIDIOLEX® (CANNABIDIOL) PATENTS; 26/03/2018 – Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model; 18/04/2018 – INSYS THERAPEUTICS TO ADVANCE RESEARCH OF DRONABINOL INHALATION; 08/05/2018 – INSYS, LUNATUS TO COMMERCIALIZE SUBSYS SPRAY IN MIDDLE EAST; 08/03/2018 – Insys Therapeutics 4Q Loss/Shr 65c; 08/05/2018 – INSYS Therapeutics Announces Exclusive License Partnership With Lunatus to Commercialize SUBSYS (Fentanyl Sublingual Spray) in the Middle East

Investors sentiment increased to 1.31 in 2018 Q2. Its up 0.52, from 0.79 in 2018Q1. It increased, as 18 investors sold GRMN shares while 108 reduced holdings. 47 funds opened positions while 118 raised stakes. 75.52 million shares or 5.99% more from 71.26 million shares in 2018Q1 were reported. Hussman Strategic Advsr reported 51,050 shares or 0.84% of all its holdings. 170 are owned by Mitsubishi Ufj Securities Holding Limited. Wolverine Asset Management Ltd Liability Corporation has invested 0.01% in Garmin Ltd. (NASDAQ:GRMN). 107 were accumulated by Huntington Commercial Bank. Prudential Public Ltd has invested 0.02% in Garmin Ltd. (NASDAQ:GRMN). 10,278 were accumulated by Natixis Advsr Ltd Partnership. Omers Administration has invested 0.03% in Garmin Ltd. (NASDAQ:GRMN). Moreover, Ameriprise Fincl has 0% invested in Garmin Ltd. (NASDAQ:GRMN) for 67,670 shares. Price T Rowe Associate Md owns 172,979 shares. 61,244 are held by Voloridge Investment Ltd Company. Moody Bancorp Tru Division holds 0.01% of its portfolio in Garmin Ltd. (NASDAQ:GRMN) for 4,000 shares. Bluecrest Cap Mgmt Limited holds 9,691 shares. South Texas Money has invested 1.46% in Garmin Ltd. (NASDAQ:GRMN). 9,916 are owned by World Asset Mgmt Inc. Wells Fargo Mn holds 0.01% of its portfolio in Garmin Ltd. (NASDAQ:GRMN) for 499,964 shares.

Since May 17, 2018, it had 0 buys, and 32 selling transactions for $403.09 million activity. On Wednesday, October 31 KAO MIN H sold $44.86M worth of Garmin Ltd. (NASDAQ:GRMN) or 678,401 shares. 3,884 Garmin Ltd. (NASDAQ:GRMN) shares with value of $252,460 were sold by Desbois Patrick. PEMBLE CLIFTON A sold $1.09 million worth of stock. Bartel Danny J also sold $92,397 worth of Garmin Ltd. (NASDAQ:GRMN) on Thursday, May 17. Huang Pao-Chang sold $143,023 worth of stock or 2,375 shares.

More notable recent Garmin Ltd. (NASDAQ:GRMN) news were published by: which released: “Could a Partnership Save GoPro?” on November 17, 2018, also with their article: “Better Buy: Garmin Ltd. vs. Fitbit Inc.” published on November 04, 2018, published: “Garmin Ltd. 2018 Q3 – Results – Earnings Call Slides” on October 31, 2018. More interesting news about Garmin Ltd. (NASDAQ:GRMN) were released by: and their article: “Garmin ranks among nation’s most reputable tech companies” published on November 08, 2018 as well as‘s news article titled: “Garmin opens warehouse and manufacturing facility at Olathe HQ [PHOTOS]” with publication date: October 24, 2018.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *